What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

Intellia Therapeutics Loses Technology Patent and Suffers a Selloff
A selloff of Intellia Therapeutics (NTLA) stock occured when the U.S. Patent and trademark office ruled that CRISPR genome editing technology patent belongs to the Broad Institute. It's stating that a team of researchers led by Feng Zhang beat Jennifer Doudna and Emmanuelle Charpentier in making CRISPR editing possible.

This new . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.